Macrogenics (MGNX) Share-based Compensation (2012 - 2026)
Macrogenics (MGNX) posted quarterly Share-based Compensation of $2.6 million for Q1 2026, down 39.67% year-over-year from $4.4 million in Q1 2025, and up 123.34% quarter-over-quarter from -$11.3 million in Q4 2025.
Macrogenics (MGNX) Share-based Compensation (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Share-based Compensation for 15 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation fell 39.67% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at -$1.5 million (down 104.62% YoY), while the FY2025 annual figure was $288000.0, down 99.02% from the prior year.
- Share-based Compensation grew to $2.6 million in Q1 2026 per MGNX's latest filing, from -$11.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $15.7 million in Q3 2022 and bottomed at -$11.3 million in Q4 2025.
- Historically, Share-based Compensation has averaged $4.7 million across 5 years, with a median of $4.7 million in 2022.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 1413.29% — and 2025, when it tumbled 200.64%.
- Macrogenics' Share-based Compensation stood at $4.7 million in 2022, then fell by 8.06% to $4.4 million in 2023, then jumped by 158.43% to $11.3 million in 2024, then sank by 200.64% to -$11.3 million in 2025, then soared by 123.34% to $2.6 million in 2026.
- Business Quant data shows MGNX's Share-based Compensation at $2.6 million in Q1 2026, -$11.3 million in Q4 2025, and $11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | 2.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.65 Mn |
| Mar 31, 2026 | 2.65 Mn |
| Dec 31, 2025 | -11.34 Mn |
| Dec 31, 2025 | -11.34 Mn |
| Sep 30, 2025 | 11.34 Mn |
| Sep 30, 2025 | 11.34 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Mar 31, 2025 | 4.39 Mn |
| Mar 31, 2025 | 4.39 Mn |
| Dec 31, 2024 | 11.27 Mn |
| Dec 31, 2024 | 11.27 Mn |
| Sep 30, 2024 | 5.97 Mn |
| Sep 30, 2024 | 5.97 Mn |
| Jun 30, 2024 | 9.81 Mn |
| Jun 30, 2024 | 9.81 Mn |
| Mar 31, 2024 | 2.39 Mn |
| Mar 31, 2024 | 2.39 Mn |
| Dec 31, 2023 | 4.36 Mn |
| Dec 31, 2023 | 4.36 Mn |